Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 7, 2004, Pages 777-784

  Van Ryn, Joanne ^a,b   Kink Eiband, Monika ^a   Kuritsch, Ingrid ^a   Feifel, Ulrich ^a   Hanft, Gertraud ^a   Wallenstein, Gudrun ^a   Trummlitz, Guenter ^a   Pairet, Michel ^a  

^a B Ingelheim Pharma GmbH/Co KG   (Germany)

^b B Ingelheim Pharma GmbH/Co KG   (Germany)

Author keywords

Antiplatelet effect; Aspirin; COX 1; Drug interactions; Meloxicam; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DUP 698; IBUPROFEN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; INHIBITION KINETICS; MALE; NORMAL HUMAN; OPEN STUDY; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; XEROSTOMIA;

ADULT; ASPIRIN; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; FEMALE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THIAZINES; THIAZOLES; THROMBOXANE B2;

EID: 2942642591     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266623     Document Type: Article

References (31)

1. Antiplatelet Trialists' Group: Prevention of death, myocardial infarction and stroke by antiplatelet therapy in high risk patients. BMJ 2002;324:71-86.
2. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119(Suppl.):39S-63S.
3. Hayden M, Pignone M, Phillips C, Mulrow C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:161-172.
4. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
5. Parks WM, Hoak JC, Czervionke RL: Comparative effect of ibuprofen on endothelial and platelet prostaglandin synthesis. J Pharm Exp Ther 1981;219:415-419.
6. Rao GH, Johnson GG, Reddy KR, White JG: Ibuprofen protects cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983;3:383-388.
7. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, et al: Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108:1191-1195.
8. MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-574.
9. Ouellet M, Riendeau D, Percival MD: A high level of cyclooxygenase-1 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 2001;98:14583-14588.
10. Livio M, Del Maschio A, Cerletti C, de Gaetano G: Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982;23:787-796.
11. Engelhardt G, Boegel R, Schnitzler C, Utzmann R: Meloxicam: Influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996;51:29-38.
12. Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G: Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 1998;47:270-276.
13. Hawkey C, Kahan A, Steinbrueck K, Alegre C, Baumelou E, Begaud B, et al: Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998;37:937-945.
14. Dequeker J, Hawkey C, Kahan A, Steinbrueck K, Alegre C, Baumelou E, et al: Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-951.
15. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, et al: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-1120.
16. de Meijer A, Vollaard H, de Metz M, Verbruggen B, Thomas C, Novakova I: Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin Pharmacol Ther 1999;66:425-430.
17. Rinder HM, Tracey JB, Souhrada M, Wang C, Gagnier RP, Wood CC: Effects of meloxicam on platelet function in healthy adults: a randomised, double-blind, placebo-controlled trial. J Clin Pharmacol 2002;42:881-886.
18. Born GVR, Cross MJ: The aggregation of blood platelets. J Physiol 1963;168:178-195.
19. Roth GJ, Calverley DC: Aspirin, platelets, and thrombosis: theory and practice. Blood 1994;83:885-898.
20. Pedersen AK, FitzGerald GA: Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206-1211.
21. Clutton P, Folts JD, Freedman JE: Pharmacological control of platelet function. Pharmacol Res 2001;44:255-264.
22. Davies NM: Clinical pharmacokinetics of ibuprofen: the first 30 years. Clin Pharmacokinet 1998;34:101-154.
23. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA: Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989.
24. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Zi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk of cardiovascular events. Circulation 2002;105:1650-1655.
25. Tegeder I, Loetsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G: Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther 1999;65:533-544.
26. Trummlitz G, van Ryn J: Designing selective COX-2 inhibitors: molecular modeling approaches. Curr Opin Drug Discov Devel 2002;5:550-561.
27. Burde T, Rimon G: On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1. Eur J Pharmacol 2002;453:167-173.
28. Degner F, Sigmund R, Zeidler H: Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther 2000;22:400-410.
29. Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one-year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 1999;38:235-244.
30. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P: Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch Intern Med 2000;160:2947-2954.
31. Schoenfeld P: Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999;107:48S-54S.